Palisade Bio, Inc. (NasdaqCM: PALI)
Health Care · Biotechnology · US
$1.54
+6.94% today · -16.8% 1Y
Palisade Bio, Inc. (NasdaqCM: PALI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $268.38M and employs 14 people.
Over the last twelve months the share price has lost 16.8%, trading between 1.32 and 2.86.
Tweenvest scores Palisade Bio, Inc. across four factors: quality 46/100, value 54/100. Its strongest factor is value.
PALI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $268.38M
- Revenue (TTM)
- $500.00K
- P/E
- —
- EPS
- -0.20
- Dividend yield
- —
- Beta (5Y)
- 1.62
- 52-week high
- $2.86
- 52-week low
- $1.32
- Avg volume (3M)
- —
- Shares outstanding
- 174.27M
- Employees
- 14
- Next earnings
- —
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
- ISIN
- US6963894026
- Founded
- 2001
- Listed since
- Mar 30, 2007
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Larimar Therapeutics, Inc.NasdaqGM: LRMR | $278.70M | $2.67 | -9.80% |
| Vanda Pharmaceuticals Inc.NasdaqGM: VNDA | $276.31M | $4.57 | -1.30% |
| Bicycle Therapeutics plcNasdaqGS: BCYC | $272.27M | $3.89 | +2.10% |
| SAB Biotherapeutics, Inc.NasdaqCM: SABS | $271.14M | $2.98 | 0.00% |
| Northwest Biotherapeutics, Inc.OTCPK: NWBO | $267.79M | $0.16 | +2.15% |
| Century Therapeutics, Inc.NasdaqCM: IPSC | $266.18M | $1.47 | -3.92% |
| Mabpharm LimitedSEHK: 2181 | $265.39M | HK$0.51 | +3.06% |
| BridgeBio Oncology Therapeutics, Inc.NasdaqGM: BBOT | $265.38M | $3.31 | -14.91% |
Figures last refreshed Oct 11, 2026.